Navigation Links
Perrigo Expands Infant Formula Distribution in China With Founder Group
Date:10/19/2011

ALLEGAN, Mich., Oct. 19, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has entered into a supply agreement with Founder Pharma Co., Ltd., a wholly owned subsidiary of publicly listed Southwest Synthetic Pharmaceutical Corp., Ltd. (SZSE: 000788).  Perrigo will supply infant formula manufactured in its U.S. facilities, for sale and distribution by Founder Pharma in China.

Perrigo Chairman and CEO Joseph C. Papa stated, "Southwest Synthetic is an exciting partner given its strong reputation and healthcare focus. Perrigo's high quality products and Southwest Synthetic's strong brand, marketing, and distribution should be a winning combination in the world's most robust infant formula market."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Southwest Synthetic is located in Chongqing, China and is the largest manufacturing, R&D, and exporting enterprise of biological and chemical synthetic pharmaceutical products in southwest China. It is also a key enterprise in China's pharmaceutical industry and is one of China's pharmaceutical enterprises with the most international approvals. In the past 2 to 3 years, it has completed two consolidations and built an industry chain from biological and chemical pharmaceuticals to healthcare products distribution. Visit Southwest Synthetic on the Internet (http://www.fsspc.com/en/)

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company Will Release First Quarter Fiscal 2012 Results On October 27, 2011
2. Perrigo Company Confirms FDA Tentative Approval for Clobetasol Propionate Emulsion Foam
3. Perrigo to Host Analyst Day on October 5, 2011 at the TASE, Tel Aviv Stock Exchange in Tel Aviv, Israel
4. Perrigo to Host Analyst Day on September 27, 2011 at the NASDAQ MarketSite in Times Square
5. Perrigo Announces FDA Final Approval for Ketoconazole Foam, 2%
6. Perrigo Company Will Release Fourth Quarter Fiscal 2011 Results on August 16, 2011
7. Watson Enters into Agreement to Acquire Products Related to Perrigos Acquisition of Paddock Laboratories
8. Perrigo Closes Acquisition of Paddock Labs
9. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
10. Perrigo Provides Update on Acquisition of Paddock Labs
11. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a ... cells and other difficult to transfect cells, announces its launch of the PluriQ™ ... Gene Editing System is a complete system for culturing and transfecting human ...
Breaking Medicine News(10 mins):